40. 高安動脈炎
［臨床試験数：22，薬物数：46（DrugBank：20），標的遺伝子数：22，標的パスウェイ数：111］
Searched query = "Takayasu arteritis", "Aortitis syndrome", "Pulseless disease"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04564001 (ClinicalTrials.gov) | September 2020 | 21/9/2020 | Multicentre, Randomized, Prospective Trial Evaluating the Efficacy and Safety of Infliximab to Tocilizumab in Refractory or Relapsing Takayasu Arteritis | Multicentre, Randomized, Prospective Trial Evaluating the Efficacy and Safety of Infliximab to Tocilizumab in Refractory or Relapsing Takayasu Arteritis | Takayasu Arteritis | Drug: Infliximab;Drug: Tocilizumab | Assistance Publique - Hôpitaux de Paris | NULL | Not yet recruiting | 18 Years | N/A | All | 50 | Phase 2 | NULL |
| 2 | NCT04300686 (ClinicalTrials.gov) | March 1, 2020 | 5/3/2020 | A Pilot Study in Severe Patients With Takayasu Arteritis. | A Pilot Study in the Treatment of Severe Patients With Takayasu Arteritis With Tocilizumab and Adalimumab, Based on ECTA Cohort | Takayasu Arteritis;Tocilizumab;Adalimumab;Treatment | Biological: Tocilizumab;Biological: Adalimumab | Shanghai Zhongshan Hospital | NULL | Recruiting | 14 Years | 100 Years | All | 40 | Phase 4 | China |
| 3 | NCT04299971 (ClinicalTrials.gov) | March 1, 2020 | 5/3/2020 | Efficiency of Methotrexate and Tofacitinib in Mild and Moderate Patients | Randomized Open-label Study in Mild and Moderate Patients With Takayasu Arteritis Between Methotrexate and Tofacitinib Based on the ECTA Cohort. | Takayasu Arteritis;Methotrexate;Inhibition;Treatment | Drug: Methotrexate Tablets;Drug: Tofacitinib tablet | Shanghai Zhongshan Hospital | NULL | Recruiting | 14 Years | 100 Years | All | 130 | Phase 4 | China |
| 4 | NCT04161898 (ClinicalTrials.gov) | February 4, 2020 | 12/11/2019 | A Study to Evaluate the Efficacy and Safety of Upadacitinib in Subjects With Takayasu Arteritis (TAK) | A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Upadacitinib in Subjects With Takayasu Arteritis (SELECT-Takayasu) | Takayasu Arteritis (TAK) | Drug: Upadacitinib;Drug: Placebo for Upadacitinib;Drug: Prednisolone | AbbVie | NULL | Recruiting | 18 Years | N/A | All | 56 | Phase 3 | Japan;Korea, Republic of |
| 5 | NCT04137614 (ClinicalTrials.gov) | November 30, 2019 | 22/10/2019 | Drug-coated Balloon for Takayasu Arteritis Associated Renal Artery Stenosis | The Effects and Safety of Drug-coated Balloon in the Treatment of Hypertension Caused by Takayasu Arteritis Associated Renal Artery Stenosis: a Single Centre, Random, Double Blind Trial | Takayasu Arteritis | Procedure: Drug coated balloon (DCB);Procedure: Digital substraction angiography (DSA) | Shanghai Zhongshan Hospital | NULL | Not yet recruiting | 18 Years | 60 Years | All | 30 | N/A | China |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 6 | EUCTR2018-003753-13-FR (EUCTR) | 19/03/2019 | 13/12/2018 | INTOReTAK : INfliximab and TOcilizumab in Refractory/relapsing TAKayasu arteritis | Multicentre, randomized, prospective trial comparing the efficacy and safety of Infliximab to tocilizumab in refractory or relapsing Takayasu arteritis | Patients with refractory or relapsing Takayasu Arteritis desease;Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Therapeutic techniques [E02] | Trade Name: RoActemra 20mg/ml Product Name: Tocilizumab INN or Proposed INN: Tocilizumab Other descriptive name: TOCILIZUMAB Product Name: Infliximab INN or Proposed INN: INFLIXIMAB | ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 50 | Phase 3 | France | ||
| 7 | NCT03482479 (ClinicalTrials.gov) | February 4, 2019 | 22/3/2018 | Low Dose Naltrexone to Improve Physical Health in Patients With Vasculitis | Low Dose Naltrexone to Improve Physical Health in Patients With Vasculitis | Eosinophilic Granulomatosis With Polyangiitis (EGPA);Churg-Strauss Syndrome (CSS);Giant Cell Arteritis;Granulomatosis With Polyangiitis;Microscopic Polyangiitis;Polyarteritis Nodosa;Takayasu Arteritis | Drug: Naltrexone Hydrochloride;Other: Placebo Comparator | University of Pennsylvania | NULL | Recruiting | 18 Years | N/A | All | 36 | Phase 2 | United States |
| 8 | NCT03550781 (ClinicalTrials.gov) | June 1, 2018 | 5/5/2018 | Anti-inflammatory Treatment for Inactive Takayasu Arteritis | Does Inactive Takayasu Arteritis(NIH Criteria) Need Anti-inflammatory Treatment? | Takayasu Arteritis;Anti-Inflammatory Agents | Drug: Prednisone, cyclophosphamide | Chinese Academy of Medical Sciences, Fuwai Hospital | NULL | Not yet recruiting | 10 Years | 40 Years | All | 40 | Phase 2;Phase 3 | NULL |
| 9 | NCT03430388 (ClinicalTrials.gov) | January 31, 2018 | 30/1/2018 | Yellow Fever Vaccine in Patients With Rheumatic Diseases | Evaluation of Yellow Fever Vaccine in Patients With Rheumatic Diseases Under Low Immunosuppression Level and Residing in a Risk Area | Systemic Lupus;Rheumatoid Arthritis;Spondyloarthritis;Inflammatory Myopathy;Systemic Sclerosis;Mixed Connective Tissue Disease;Takayasu Arteritis;Granulomatosis With Polyangiitis;Sjogren's Syndrome;Juvenile Idiopathic Arthritis;Juvenile Dermatomyositis | Biological: Yellow Fever vaccine (17D) | University of Sao Paulo General Hospital | NULL | Completed | 2 Years | 60 Years | All | 600 | N/A | Brazil |
| 10 | NCT03096275 (ClinicalTrials.gov) | March 16, 2017 | 13/3/2017 | Comparison of Mycophenolate Mofetil and Cyclophosphamide for Active Takayasu's Arteritis | Comparison of the Efficacy of Mycophenolate Mofetil Combined With Methotrexate and Cyclophosphamide for the Treatment of Takayasu's Arteritis | Takayasu Arteritis | Drug: MMF;Drug: CYC;Drug: Glucocorticoids;Drug: MTX;Drug: AZA | Chinese SLE Treatment And Research Group | Peking Union Medical College Hospital | Recruiting | 18 Years | N/A | All | 150 | Phase 3 | China |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 11 | NCT03192878 (ClinicalTrials.gov) | March 1, 2017 | 9/5/2017 | Infliximab Biosimilar in Takayasu's Arteritis | A Prospective Observational Study of Infliximab Biosimilar in the Treatment of Takayasu's Arteritis Resistant to Corticosteroids and Conventional Immune-suppressive Treatments | Takayasu Arteritis | Drug: Infliximab | Ospedale San Raffaele | NULL | Recruiting | 18 Years | N/A | All | 30 | N/A | Italy |
| 12 | JPRN-UMIN000025940 | 2017/02/07 | 07/02/2017 | Clinical Research on the Safety of anti-interleukin-6 antibody (Tocilizumab) treatment for the refractory patients with Takayasu Arteritis | Clinical Research on the Safety of anti-interleukin-6 antibody (Tocilizumab) treatment for the refractory patients with Takayasu Arteritis - TOCIlizumab treatment for TAKayasu arteritis (TOCI-TAK) | Takayasu arteritis | Intravenous administration of tocilizumab (8mg/kg/month) for up to 12 months | Osaka University | National Cerebral and Cardiovascular Center | Complete: follow-up continuing | 16years-old | 60years-old | Male and Female | 2 | Not selected | Japan |
| 13 | NCT02981979 (ClinicalTrials.gov) | December 2016 | 22/11/2016 | Takayasu Arteritis Clinical Trial in China | Comparison of the Efficacy and Safety of Leflunomide Versus Placebo Combine With the Basic Prednisone Therapy in Patients With Active Phase of Takayasu's Arteritis: a Randomized Controlled Double-blinded Trial | Takayasu Arteritis | Drug: Leflunomide 10mg Tab;Drug: Prednisone Acetate;Drug: Placebos | Jiang lindi | NULL | Unknown status | 18 Years | 65 Years | All | 116 | N/A | China |
| 14 | NCT03893136 (ClinicalTrials.gov) | November 1, 2016 | 12/3/2019 | The Registry Study of Takayasu Arteritis in East China | The Cohort Study of East Chinese Takayasu's Arteritis (ECTA-cohort Study) | Takayasu Arteritis;Mechanisms, Defense;Pregnancy Related;Treatment Refusal;Outcome | Biological: Tocilizumab;Drug: Leflunomide | Shanghai Zhongshan Hospital | NULL | Recruiting | 18 Years | 65 Years | All | 1000 | China | |
| 15 | NCT02925351 (ClinicalTrials.gov) | January 25, 2016 | 8/9/2016 | Fluorine F 18 Clofarabine PET/CT in Imaging Patients With Autoimmune or Inflammatory Diseases | The Biodistribution of 18F-Clofarabine in Patients With Autoimmune and Inflammatory Diseases | Autoimmune Disease;Crohn Disease;Inflammatory Disorder;Rheumatoid Arthritis;Systemic Lupus Erythematosus;Takayasu Arteritis | Procedure: Computed Tomography;Radiation: Fluorine F 18 Clofarabine;Procedure: Positron Emission Tomography | Jonsson Comprehensive Cancer Center | NULL | Completed | 18 Years | N/A | All | 8 | Early Phase 1 | United States |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 16 | NCT02457585 (ClinicalTrials.gov) | March 2015 | 18/5/2015 | Clinical Study of Anti-tumor Necrosis Factor Therapy in Patients With Takayasu Arteritis | Anti-tumor Necrosis Factor Therapy Effect on Takayasu Arteritis | Takayasu's Arteritis | Drug: remicade (anti tumor necrosis factor inhibitor) | Seoul National University Hospital | NULL | Recruiting | 18 Years | N/A | All | 11 | Phase 2 | Korea, Republic of |
| 17 | JPRN-JapicCTI-142616 | 02/10/2014 | 23/07/2014 | Phase III Study of MRA-SC in Patients with Takayasu Arteritis | A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Phase III Study of MRA-SC in Patients with Takayasu Arteritis | Takayasu Arteritis | Intervention name : tocilizumab (MRA-SC) INN of the intervention : tocilizumab Dosage And administration of the intervention : 162mg/W, SC Control intervention name : Placebo INN of the control intervention : - Dosage And administration of the control intervention : Placebo/W, SC | Chugai Pharmaceutical Co., Ltd. | NULL | complete | 12 | BOTH | 34 | Phase 3 | Japan | |
| 18 | JPRN-UMIN000025943 | 2014/08/07 | 07/02/2017 | Long-term Safety of treatment with tocilizumab in the refractory patients with Takayasu Arteritis | Long-term Safety of treatment with tocilizumab in the refractory patients with Takayasu Arteritis - Long-term ACTemra Investigation for remissION introduction in TAKayasu Arteritits (LACTION-TAK) | Takayasu arteritis | Intravenous administration of tocilizumab (8mg/kg/month) will be performed until December 31st, 2017. | Osaka Unversity | National Cerebral and Cardiovascular Center | Complete: follow-up continuing | 16years-old | 60years-old | Male and Female | 9 | Not selected | Japan |
| 19 | NCT02101333 (ClinicalTrials.gov) | June 10, 2014 | 17/2/2014 | Efficacy and Tolerance of Tocilizumab In Takayasu Arteritis | Efficacy and Tolerance of First-line Treatment With Tocilizumab in Active Takayasu Arteritis French Prospective Multicenter Study | TAKAYASU ARTERITIS | Drug: Tocilizumab | Assistance Publique - Hôpitaux de Paris | Chugai Pharmaceutical | Completed | 18 Years | 77 Years | All | 18 | Phase 3 | France |
| 20 | JPRN-UMIN000008812 | 2012/10/01 | 01/10/2012 | Efficacy and safety of tocilizumab mono-therapy in patients with large vessel vasculitis (LVV; giant cell arteritis or Takayasu arteritis) and polymyalgia rheumatica (PMR) | Rheumatoid arthritis | tocilizumab monotherapy | Department of Rheumatology & Clinical ImmunologySaitama Medical Center, Saitama Medical Universitity | NULL | Complete: follow-up complete | 16years-old | 80years-old | Male and Female | 40 | Not selected | Japan | |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 21 | JPRN-UMIN000007845 | 2012/05/01 | 01/05/2012 | Efficacy and Safety of treatment with tocilizumab in refractory patients with Takayasu Arteritis | Efficacy and Safety of treatment with tocilizumab in refractory patients with Takayasu Arteritis - ACTemra Investigation for remissiON introduction in Takayasu Arteritits (ACTION-TA) | Takayasu arteritis | Intravenous administration of tocilizumab (8mg/kg/month) for 24 months | Department of Cardiovascular Medicine Graduate School of Medicine Osaka University | NULL | Complete: follow-up continuing | 16years-old | 60years-old | Male and Female | 15 | Not selected | Japan |
| 22 | NCT00006055 (ClinicalTrials.gov) | March 2000 | 5/7/2000 | Autologous Peripheral Blood Stem Cell Transplantation in Patients With Life Threatening Autoimmune Diseases | Purpura, Schoenlein-Henoch;Graft Versus Host Disease;Anemia, Hemolytic, Autoimmune;Rheumatoid Arthritis;Churg-Strauss Syndrome;Hypersensitivity Vasculitis;Wegener's Granulomatosis;Systemic Lupus Erythematosus;Giant Cell Arteritis;Pure Red Cell Aplasia;Juvenile Rheumatoid Arthritis;Polyarteritis Nodosa;Autoimmune Thrombocytopenic Purpura;Takayasu Arteritis | Drug: anti-thymocyte globulin;Drug: cyclophosphamide;Drug: cyclosporine;Drug: filgrastim;Drug: methylprednisolone;Drug: prednisone;Procedure: Autologous Peripheral Blood Stem Cell Transplantation | Fairview University Medical Center | NULL | Active, not recruiting | 1 Year | 55 Years | Both | 10 | N/A | United States |